HCPLive Network

Appropriate Use Criteria Established for Amyloid PET

 
TUESDAY, Jan. 29 (HealthDay News) -- Experts have agreed upon appropriate use criteria for positron emission tomography (PET) of brain amyloid β, according to a report published online Jan. 28 in Alzheimer's & Dementia.

Keith A. Johnson, M.D., from Massachusetts General Hospital in Boston, and colleagues, together with the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging, convened the Amyloid Imaging Task Force to provide guidance to dementia care practitioners, patients, and caregivers. Peer-reviewed, published literature was reviewed to develop a consensus opinion about the use of amyloid PET in specific clinical scenarios.

The researchers developed and agreed upon a series of specific appropriate use criteria to define the patients and clinical circumstances in which amyloid PET could be used. Amyloid imaging is appropriate when the following criteria are met: there is evidence of a cognitive complaint with objectively confirmed impairment; when Alzheimer's disease is a possible diagnosis, but that diagnosis is uncertain after a comprehensive evaluation by an expert; and when knowledge of amyloid pathology is likely to increase diagnostic certainty and alter management.

"Because both dementia care and amyloid PET technology are in active development, these appropriate use criteria will require periodic reassessment," the authors write. "Future research directions are also outlined, including diagnostic utility and patient-centered outcomes."

Multiple Task Force members and reviewers disclosed financial ties to pharmaceutical and other health care companies.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 

Further Reading
Researchers assessed the effect of seizure status and severity, medication use, mental health indicators, parental support, and other factors on self-reported quality of life in children with epilepsy.
A group of international researchers led by Luosheng Li, MD, of the Rolf Luft Research Center for Diabetes and Endocrinology at the Karolinska Institutet, Karolinska University Hospital in Stockholm, Sweden, recently demonstrated that age-dependent decline in insulin secretion (and thus glucose homeostasis) from the beta cell in experimental mice models is associated with subtle changes in Ca2+ dynamics.
For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), the right treatment can make a world of difference in the management of their condition. A recent study looked at how effective inhaled budesonide and systemic methylprednisolone can be for those patients.
More Reading